Tue, 29 Nov, 2016, 08:30 - English - Diamyd Medical has appointed FNCA Sweden AB as Certified Adviser
November 29, 2016 at 03:28 am EST
Share
Diamyd Medical AB changes the Certified Adviser at Nasdaq Stockholm First North. FNCA Sweden AB (www.fnca.se) begins its commitment as of December 2, 2016.
About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.
Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Six clinical studies are ongoing with Diamyd®. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB (former Cellaviva AB). Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.
Diamyd Medical's B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company's Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: www.diamyd.com
Attachments:
PDF version
Diamyd Medical AB published this content on 29 November 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 29 November 2016 08:27:35 UTC.
Original documenthttp://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=2378664
Public permalinkhttp://www.publicnow.com/view/C1AF949116AB25B96CD74774B2EDABDAE2AE4AF8
Mertiva AB, formerly Diamyd Medical AB, is a Sweden-based company active within the healthcare sector. As of August 31, 2013, the Company owned 8% shares of the United-States based Protein Sciences Corporation, as well as 19% shares of Mercodia AB. The Company changed its name in May 2013. Additionally, its subsidiary, Diamyd Therapeutics, was spun off and changed its name to Diamyd Medical.